key: cord-0765586-nrnga4av authors: Osmanov, I. M.; Spiridonova, E.; Bobkova, P.; Gamirova, A.; Shikhaleva, A.; Andreeva, M.; Blyuss, O.; El-Taravi, Y.; DunnGalvin, A.; Comberiati, P.; Peroni, D. G.; Apfelbacher, C.; Genuneit, J.; Mazankova, L.; Miroshina, A.; Chistyakova, E.; Samitova, E.; Borzakova, S.; Bondarenko, E.; Korsunskiy, A. A.; Konova, I.; Hanson, S. W.; Carson, G.; Sigfrid, L.; Scott, J. T.; Greenhawt, M.; Whittaker, E. A.; Garralda, E.; Swann, O.; Buonsenso, D.; Nicholls, D. E.; Simpson, F.; Jones, C.; Semple, M. G.; Warner, J. O.; Vos, T.; Olliaro, P.; Munblit, D.; Team, Sechenov StopCOVID Research title: Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study date: 2021-04-26 journal: nan DOI: 10.1101/2021.04.26.21256110 sha: fd1b6d10d7cb4ce36bc8069596e8cd847db6c69a doc_id: 765586 cord_uid: nrnga4av Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors. Methods This is a prospective cohort study of children (18 years old and younger) admitted with confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow, Russia. Children admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow up survey. Persistent symptoms (>5 months) were further categorised by system(s) involved. Findings Overall, 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3-15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: age "6-11 years" (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and "12-18 years" (2.68, 1.41 to 5.4), and a history of allergic diseases (1.67, 1.04 to 2.67). Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up. Our findings highlight the need for replication and further investigation of potential mechanisms as well as clinical support to improve long term outcomes in children. Funding None. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 S e c h e n o v S t o p C O V I D R e s e a r c h T e a m ( G r o u p a u t h o r s ) 69 E l i n a A b d e e v a 1 , N i k o l A l e k s e e v a 1 , A n a s t a s i i a B a i r a s h e v s k a i a 1 , D i n a B a i m u k h a m b e t o v a 1 , 70 L u s i n e B a z i y a n t s 1 , A n n a B e r b e n y u k 1 , T a t i a n a B e z b a b i c h e v a 1 , J u l i a C h a y k a 1 , S a l i m a 71 D e u n e z h e w a 1 , Y u l i a F i l i p p o v a 1 , S v e t l a n a G a d e t s k a y a 2 , A n a s t a s i a G o r i n a 1 , C y r i l l G o r l e n k o 1 , 72 Y u l i a V I v a n o v a 2 , M a r g a r i t a K a l i n i n a 1 , B o g d a n K i r i l l o v 1 , H e r m a n K i s e l j o w 1 , N a t a l y a K o g u . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 A B S T R A C T 94 B a c k g r o u n d T h e l o n g -t e r m s e q u e l a e o f c o r o n a v i r u s d i s e a s e 2 0 1 9 ( C o v i d -1 9 ) i n c h i l d r e n 95 r e m a i n p o o r l y c h a r a c t e r i s e d . T h i s s t u d y a i m e d t o a s s e s s l o n g -t e r m o u t c o m e s i n c h i l d r e 123 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. ; https://doi.org/10.1101/2021.04.26.21256110 doi: medRxiv preprint e m i c h a s , a t t h e t i m e o f w r i t i n g , a f f e c t e d o v e r 1 3 5 m i l l i o n p e o p l e 126 w o r l d w i d e 1 , w i t h a d v e r s e i m p a c t s o n p h y s i c a l a n d p s y c h o l o g i c a l h e a l t h a n d o v e r 3 m i l l i o . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) W e p e r f o r m e d m u l t i v a r i a b l e l o g i s t i c r e g r e s s i o n t o i n v e s t i g a t e a s s o c i a t i o n s o f d e m o g r a p h i c 232 c h a r a c t e r i s t i c s , c o -m o r b i d i t i e s ( l i m i t e d t o t h o s e r e p o r t e d i n ≥ 5 % o f p a r t i c i p a n t s ) , p r e s e n c e o f 233 p n e u m o n i a d u r i n g a c u t e i n f e c t i o n a n d s e v e r i t y o f C o v i d -1 9 w i t h p e r s i s t e n t s y m p t o m 234 c a t e g o r i e s p r e s e n c e a t t h e t i m e o f t h e f o l l o w -u p i n t e r v i e w . W e i n c l u d e d a l l p a r t i c i p a n t s f o . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. ) . 314 315 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. T h e s c o r e s o n t h e w e l l n e s s s c a l e f o r c h i l d r e n w i t h o n e o r t w o o r m o r e p e r s i s t e n t s y m p t o m s 321 s i g n i f i c a n t l y d e c l i n e d w h e n c o m p a r e d t o b e f o r e C o v i d -1 9 o n s e t f r o m 9 0 ( 8 0 -1 0 0 ) t o 8 2 . 5 322 ( 7 0 -9 3 . 8 ) a n d f r o m 9 0 ( 8 0 -9 5 ) t o 7 0 ( 6 0 -8 0 ) ( p < 0 . 0 0 1 f o r a l l c o m p a r i s o n s ) , r e s p e c t i v e l y . 323 C h i l d r e n w h o d i d n o t e x p e r i e n c e a n y p e r s i s t e n t s y m p t o m s d i d n o t r e p o r t a n y s i g n i f i c a n . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 A m a j o r s t r e n g t h o f t h i s s t u d y i s t h a t i t w a s b a s e d o n t h e I S A R I C C O V I D -1 9 H e a l t h a n d 427 W e l l b e i n g F o l l o w U p S u r v e y f o r C h i l d r e n w h i c h w i l l a s s i s t w i t h d a t a h a r m o n i s a t i o n a n d 428 c o m p a r i s o n w i t h o t h e r i n t e r n a t i o n a l s t u d i e s i n t h e f u t u r e . A n o t h e r s t r e n g t h i s t h e l a r g e 429 s a m p l e s i z e o f c o n f i r m e d C o v i d -1 9 i n f e c t e d c h i l d r e n , a n d t h i s c o h o r t h a s t h e l o n g e s t f o l l o . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) An interactive web-based dashboard to track COVID-19 in 482 real time 6-month consequences of COVID-19 in patients 484 discharged from hospital: a cohort study Risk factors for long-term consequences 486 of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: 487 StopCOVID cohort study Long covid: WHO calls on countries to offer patients more rehabilitation Prevalence of ongoing symptoms following coronavirus (COVID-19) 493 infection in the UK: 1 Severe and fatal forms of COVID-19 in 498 children Coronavirus Disease 2019 in Children 500 Cared for at Texas Children's Hospital: Initial Clinical Characteristics and Outcomes Clinical characteristics of children and young 503 people admitted to hospital with covid-19 in United Kingdom: prospective multicentre 504 observational cohort study COVID-19 in children and 506 adolescents in Europe: a multinational, multicentre cohort study Hospitalization Rates and Characteristics of 509 Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 510 14 States Multisystem Inflammatory Syndrome in 512 U.S. Children and Adolescents Post-acute COVID-19 516 outcomes in children with mild and asymptomatic disease Characterising long-term covid-19: a 519 rapid living systematic review Consequences of COVID-19 infection 524 for child health and wellbeing: protocol for a prospective, observational, longitudinal study in 525 children StopCOVID cohort: An observational 527 study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city 528 for suspected COVID-19 infection The REDCap consortium: Building an 530 international community of software platform partners Research 532 electronic data capture (REDCap)--a metadata-driven methodology and workflow process 533 for providing translational research informatics support Management of post-acute 539 covid-19 in primary care Outpatient rehabilitative treatment of chronic 541 fatigue syndrome (CFS/ME) Age Groups for Pediatric Trials Preliminary Evidence on Long Covid in 545 children Somatic complaints in anxious youth Long Covid in adults discharged from UK 549 hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO 550 Clinical Characterisation Protocol 6-month neurological and 552 psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using 553 electronic health records Attributes and predictors of long COVID. Nat 555 Med 2021 Post-covid syndrome in individuals 557 admitted to hospital with covid-19: retrospective cohort study Covid-19 hyperinflammation and post-Covid-559 19 illness may be rooted in mast cell activation syndrome A c k n o w l e d g m e n t s 465 W e a r e v e r y g r a t e f u l t o t h e Z . A . B a s h l y a e v a C h i l d r e n ' s M u n i c i p a l C l i n i c a l H o s p i t a l c l i n i c a l 466 s t a f f a n d t o t h e p a t i e n t s , p a r e n t s , c a r e r s a n d f a m i l i e s f o r t h e i r k i n d n e s s a n d u n d e r s t a n d i n g 467 d u r i n g t h e s e d i f f i c u l t t i m